DrugBiological
PGDM1400LS clinical trials
Also written PGDM1400LS.
- studies test it
- 6
- open now
- 1
- in phase 3
- 0
- first study started
- 2021
Keep track of what changes. Save the PGDM1400LS studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 6
National Institute of Allergy and Infectious Diseases (NIAID) (4) · HIV Vaccine Trials Network (1) · Henry M. Jackson Foundation for the Advancement of Military Medicine (1)
Often tested with
Tested in the same studies.
VRC07-523LS (5) · PGT121.414.LS (2) · Nogapendekin alfa inbakicept (1) · Ad26.Mos4.HIV (1) · Monophosphoryl lipid A (1) · Saponin QA-21V1 (1)
Studies
Open first, then newest update. How each study uses PGDM1400LS is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1RecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT07390955Written as PGDM1400LS (IV)
- The Tatelo Plus StudyActive, not recruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06508749Written as PGDM1400LS
- A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIVActive, not recruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06812494Written as PGDM1400LS 400mg
- A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult ParticipantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05184452Written as PGDM1400LS (5mg/kg, IV)
- Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy ParticipantsSuspendedPhase 1HIV Vaccine Trials NetworkNCT05959707Written as PGDM1400LS
- Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV RemissionWithdrawnPhase 1Henry M. Jackson Foundation for the Advancement of Military MedicineNCT05769569Written as PGDM1400LS